Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd ADR (NY: RDY )

78.79 -0.74 (-0.93%)
Official Closing Price Updated: 7:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,939
Open 78.85
Bid (Size) 77.53 (1)
Ask (Size) 81.55 (1)
Prev. Close 79.53
Today's Range 78.58 - 79.39
52wk Range 63.72 - 84.46
Shares Outstanding 166,301,231
Dividend Yield 1.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily

Performance

YTD
+11.24%
+11.24%
1 Month
-4.81%
-4.81%
3 Month
+11.35%
+11.35%
6 Month
+8.21%
+8.21%
1 Year
+14.80%
+14.80%

More News

Read More
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Via Talk Markets
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr Reddy's Laboratories: Q3 Earnings Insights
Via Benzinga
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy’s Q1FY25 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)?
Via Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
Via Investor's Business Daily
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
Via Benzinga
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
From Aurigene Pharmaceutical Services Ltd.
Via Business Wire
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
Via Investor's Business Daily
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
Via InvestorPlace
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Dr. Reddy’s Q3 & 9M FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.